Improving treatment for Sjögren's disease with a new drug combination
Official title: Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone
Funded at University of Missouri-Columbia · NIH-11005215 · Data updated 2026-11-12
This study is looking at a new way to help people with Sjögren's disease by testing a combination of two treatments to reduce inflammation and improve saliva production, aiming to find the best dosage for a safer and more effective option.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $501,231 |
| NIH project number | 5R01DE033583-02 |
| Project ID | NIH-11005215 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Sjögren's disease who experience chronic inflammation and reduced saliva production.
✕Less likely to help
Patients with other autoimmune conditions unrelated to Sjögren's disease may not benefit from this research.
What this research studies
This research focuses on Sjögren's disease, an autoimmune condition that leads to inflammation and reduced saliva production. The study aims to optimize a treatment combining aspirin-triggered Resolvin D1 and dexamethasone to reduce inflammation and restore salivary gland function. By using mathematical modeling to determine the best dosage, the researchers hope to create a more effective and affordable treatment option. Patients may benefit from a safer and more effective way to manage their symptoms.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for patients suffering from Sjögren's disease.
How similar studies have gone: Previous studies have shown promise in using similar approaches to treat autoimmune conditions, indicating potential for success in this research.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Baker, Olga Juliana — University of Missouri-Columbia
- Study coordinator: Baker, Olga Juliana
Related research
Other NIH-funded projects on the same topics.
-
Refining a resolvin plus steroid treatment to help Sjögren's dry mouth
Finding the smallest effective dose of an aspirin-related molecule paired with a low steroid dose to reduce salivary gland inflammation and help people with Sjögren's make more saliva.
-
Understanding CAG repeat instability in Huntington’s disease
A Huntington’s disease study explores why the CAG repeat in the HTT gene becomes unstable and leads to earlier disease, aiming to uncover factors that influence when and how the disease starts.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.